Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer

被引:157
|
作者
Byrski, Tomasz [1 ,2 ]
Dent, Rebecca [3 ]
Blecharz, Pawel [4 ]
Foszczynska-Kloda, Malgorzata [5 ]
Gronwald, Jacek [1 ]
Huzarski, Tomasz [1 ]
Cybulski, Cezary [1 ]
Marczyk, Elzbieta [4 ]
Chrzan, Robert [6 ]
Eisen, Andrea [3 ]
Lubinski, Jan [1 ]
Narod, Steven A. [7 ]
机构
[1] Pomeranian Med Univ, Int Hereditary Canc Ctr, Dept Genet & Pathol, PL-70204 Szczecin, Poland
[2] Pomeranian Med Univ, Clin Oncol, PL-70204 Szczecin, Poland
[3] Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON M4N 3M5, Canada
[4] Curie Mem Inst, Marie Sklodowska Clin, Dept Med Oncol, PL-31115 Krakow, Poland
[5] Reg Oncol Hosp, Dept Oncol, PL-71730 Szczecin, Poland
[6] Jagiellonian Univ, Coll Med, Dept Radiol, PL-31501 Krakow, Poland
[7] Univ Toronto, Womens Coll Res Inst, Toronto, ON M5G 1N8, Canada
来源
BREAST CANCER RESEARCH | 2012年 / 14卷 / 04期
关键词
NEOADJUVANT CHEMOTHERAPY; BRCA1; MUTATIONS; OVARIAN-CANCER; FOUNDER MUTATIONS; YOUNG-WOMEN; TUMORS; RESISTANCE; FAMILIES; FEATURES; CARRIERS;
D O I
10.1186/bcr3231
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: The purpose of this investigation was to evaluate the efficacy of cisplatin chemotherapy in BRCA1 mutation carriers with metastatic breast cancer. Methods: In a phase II, open-label study, 20 patients with metastatic breast cancer who carried a mutation in BRCA1 were treated with cisplatin 75 mg/m(2) intravenously every 3 weeks as part of a 21-day cycle for 6 cycles. Restaging studies to assess response were performed after cycles 2 and 6, and every three months thereafter. Results: Between July 2007 and January 2009, 20 patients were enrolled. Baseline characteristics were as follows: 65% had prior adjuvant chemotherapy, 55% had prior chemotherapy for metastatic breast cancer; mean age was 48 years (ranges 32 to 70); 30% estrogen receptor (ER) or progesterone receptor (PR)+, 70% ER/PR/Human Epidermal Growth Factor Receptor 2 (HER2)-and 0% HER2+. Overall response rate was 80%; nine patients experienced a complete clinical response (45%) and seven experienced a partial response (35%). Overall survival was 80% at one year, 60% at two years and 25% at three years. Four of the 20 patients are alive four years after initiating treatment. The median time to progression was 12 months. The median survival from the start of cisplatinum treatment was 30 months. Cisplatin-related adverse events, including nausea (50%), anemia (5%) and neutropenia (35%) were mostly mild to moderate in severity. Conclusions: This phase II study demonstrates that cisplatin chemotherapy has high activity in women with a BRCA1 mutation and metastatic breast cancer and is generally well tolerated.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Phase II open label trial of minnelide™ in patients with chemotherapy refractory metastatic pancreatic cancer
    Propper, David
    Han, Haiyong
    Von Hoff, Daniel
    Borazanci, Erkut
    Reya, Tannishtha
    Ghergurovich, Jonathan
    Pshenichnaya, Irina
    Antal, Corina
    Condjella, Rachel
    Sharma, Shreya
    O'Dwyer, Peter
    Littlewood, Trevor
    Patel, Hitendra
    Saluja, Ashok
    Velagapudi, Mohana
    Yang, Lifeng
    Downes, Michael
    Evans, Ronald
    Evan, Gerard
    CANCER RESEARCH, 2019, 79 (13)
  • [22] Phase II open label trial of Minnelide™ in patients with chemotherapy refractory metastatic pancreatic cancer
    Propper, David
    Borazanci, Erkut
    O'Dwyer, Peter J.
    Von Hoff, Daniel
    Hartlebury, Joseph
    Antal, Corina E.
    Evan, Gerard I.
    Han, HaiYong
    Downes, Michael
    Evans, Ronald
    Rabinowitz, Joshua
    Petricoin, Emmanuel
    Saluja, Ashok
    Velagapudi, Mohana
    Patel, Hitendra
    CANCER RESEARCH, 2024, 84 (07)
  • [23] Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer
    Chan, Arlene
    Shannon, Catherine
    de Boer, Richard
    Baron-Hay, Sally
    Redfern, Andrew
    Bauwens, Astrid
    Craft, Paul
    Webb, Suzanne
    Townsend, Amanda
    Kotasek, Dusan
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (04) : 368 - 375
  • [24] A phase II, open-label trial of bortezomib (VELCADE®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer
    E. Kontopodis
    A. Kotsakis
    N. Kentepozidis
    K. Syrigos
    N. Ziras
    M. Moutsos
    G. Filippa
    A. Mala
    L. Vamvakas
    D. Mavroudis
    V. Georgoulias
    S. Agelaki
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 949 - 956
  • [25] A phase II, open-label trial of bortezomib (VELCADE®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer
    Kontopodis, E.
    Kotsakis, A.
    Kentepozidis, N.
    Syrigos, K.
    Ziras, N.
    Moutsos, M.
    Filippa, G.
    Mala, A.
    Vamvakas, L.
    Mavroudis, D.
    Georgoulias, V.
    Agelaki, S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (05) : 949 - 956
  • [26] An open-label, multicenter phase II trial of sunitinib for patients with chemorefractory metastatic gastric cancer.
    Moehler, M. H.
    Hartmann, J. T.
    Lordick, F.
    Al-Batran, S.
    Reimer, P.
    Trarbach, T.
    Ebert, M. P.
    Daum, S.
    Weihrauch, M.
    Galle, P. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [27] A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer
    Hickish, Tamas
    Cassidy, Jim
    Propper, David
    Chau, Ian
    Falk, Stephen
    Ford, Hugo
    Iveson, Tim
    Braun, Michael
    Potter, Vanessa
    Macpherson, Iain R.
    Finnigan, Helen
    Lee, Chooi
    Jones, Hilary
    Harrison, Mark
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (18) : 3136 - 3144
  • [28] An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Updated results in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
    Domchek, S. M.
    Postel-Vinay, S.
    Im, S-A
    Park, Y. Hee
    Delord, J-P
    Italiano, A.
    Alexandre, J.
    You, B.
    Bastian, S.
    Krebs, M. G.
    Waqar, S.
    Lanasa, M.
    Angell, H. K.
    Tang, M.
    Gresty, C.
    Opincar, L.
    Herbolsheimer, P.
    Kaufman, B.
    CANCER RESEARCH, 2019, 79 (04)
  • [29] Apatinib combined with taxanes and platinum neoadjuvant chemotherapy for patients with triple-negative and HER2-positive breast cancer: A multicenter, randomized, open-label, phase II trial
    Liu, Yunjiang
    Zhang, Xiangmei
    Wang, Li
    Cao, Miao
    Zhang, Shuo
    Zhang, Hui
    Zhou, Yarong
    Wang, Jintian
    CANCER RESEARCH, 2021, 81 (04)
  • [30] Apatinib added to taxanes and platinum neoadjuvant chemotherapy for patients with triple-negative and HER2-positive breast cancer: A multicenter, randomized, phase II, open-label trial
    Liu, Y.
    Zhang, X.
    Wang, L.
    Cao, M.
    Zhang, S.
    Zhang, H.
    Zhou, Y.
    Wang, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S346 - S346